Back to Freepaper Session
Micromonovision with contralateral implantation of a 2.5 add and 3.0 add apodized diffractive multifocal IOL: 6 month results
Session Title: Refractive
Session Date/Time: Sunday 16/02/2014 | 08:30-11:00
Paper Time: 10:08
Venue: Kosovel Hall (Level -2)
First Author: : AmirHamid UK
Co Author(s): : Vaishali Patel
To present results of visual performance and patient reported outcomes with 6 month follow up of patients implanted with multifocal IOL with a +2.5 Add (ReSTOR 2.5, Alcon Laboratories) in their dominant eye and a+3.0 (ReSTOR 3.0, Alcon Laboratories) Add in their non dominant eye.
Ultralase Optimax Group Daycase Theatre Facilites, Maidstone, Kent. United Kingdom
Refractive lens exchange was performed in 100 eyes of 50 patients. Surgery was performed by a single surgeon. The ReSTOR 2.5 was implanted in the dominant eye and ReSTOR 3.0 was implanted in the non dominant eye. Refraction, uncorrected visual acuity (UCVA), best corrected visual acuity (BCVA) were tested a distance ( 6m), intermediate (80cm) and near (40cm). These assesmens were performed preoperatively, 1 day, 1 week, 3 months and 6 months postoperatively. A patient satisfaction questionnaire was also used.
For eyes implanted with either IOL the BCVA was 20/20 or better in 100%. In both groups UCVA was 20/40 in 100% and 20/20 in 95% of patients. Binocular uncorrected near vision was 20/30 in 90% of patients. Binocular intermediate vision was also 20/30 for 92% of patients. 90% of patients reported complete spectacle independence.
A micromonovision approach to multifocal IOL implantation can yield excellent visual function in terms of distance, intermediate and near visual acuities. Furthermore patient reported satisfaction rates were high. FINANCIAL INTEREST: NONE